医学
肺炎
CD20
内科学
恢复期血浆
2019年冠状病毒病(COVID-19)
免疫学
胃肠病学
作者
Alessandra Oliva,Francesca Cancelli,Andrea Brogi,Ambrogio Curtolo,Giulia Savelloni,Guido Siccardi,Giulia Marcelli,Laura Mazzuti,Paolo Ricci,Ombretta Turriziani,Guido Antonelli,Mario Venditti,Claudio M Mastroianni
出处
期刊:New Microbiologica
日期:2022-01-01
卷期号:45 (1): 62-72
被引量:1
摘要
Convalescent plasma (CP) therapy might be effective in patients with haematological malignanciesand B-cell depletion. We report a single-centre experience of COVID-19 patients with non-Hodgkinlymphoma and absence of B-cells as a consequence of anti-CD20 therapy successfully treated withCP from October 2020 to May 2021. CP was given in the presence of pneumonia with respiratoryfailure despite standard treatment and consisted of three infusions on an alternate-day basis. A reviewof the current literature on this topic was also performed. Six patients were identified (medianage 59.5 years (range 50-73)). The last anti-CD20 drug administration occurred 60 days before infection(range 0-360). CP was administered after a median of 51 days (range 9-120) from SARS-CoV-2diagnosis, with an early improvement in all but one subject. We suggest a possible clinical benefitof convalescent CP treatment in COVID-19 patients with haematological malignancies and B-celldepletion having persistent/recurrent pneumonia.
科研通智能强力驱动
Strongly Powered by AbleSci AI